Article
Breastmilk transfer of cabotegravir and infant safety outcomes in mothers on cabotegravir for HIV prevention in Lilongwe, Malawi: A protocol for an observational pharmacokinetic study, CABMILK Study
2026-06-09
Abstract excerpt
<h4>Background: </h4> Long-acting injectable cabotegravir (CAB-LA) is highly effective for HIV pre-exposure prophylaxis (PrEP). However, lactating women have been underrepresented in pharmacokinetic and safety studies despite their elevated risk of HIV acquisition and potential postnatal transmission through breastfeeding. Data on cabotegravir transfer into breast milk and infant exposure remain limited. The Cabot...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 577459e0-cbfa-5e14-8dcf-85435fd12360
- DOI
- 10.12688/wellcomeopenres.25966.2
